Annual Meeting of the American Society for Clinical Oncology (ASCO)
Title: Phase 1 dose-escalation study of the safety and pharmacokinetics of PAS-004, a macrocyclic MEK inhibitor, for the treatment of patients with MAPK pathway–driven advanced solid tumors
Session: Poster Session – Developmental Therapeutics – Molecularly Targeted Agents and Tumor Biology
Poster Board: 440
Date and Time: 6/2/2025, 1:30 – 4:30 PM CDT
The full abstract will be available on the ASCO® website on May 22, 2025, at 5:00 p.m. ET.